Ochaion et al. [40] reported that A3AR agonist (1′S,2′R,3′S,4′R,5′S)-4-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide (CF502, MRS3558), via de-regulation of the NF-kB signaling pathway, inhibits fibroblast-like synoviocyte (FLS) growth and the inflammatory manifestations of arthritis, supporting the development of A3AR agonists for the treatment of rheumatoid arthritis. The gene discussed is NFKB1; the disease is Arthritis.